The ZVA said the suspension of the vaccine series No. ABV5300 was related to complications in two individuals which appeared a longer while after vaccination.
The initial assessment by the European Medicines Agency shows that there is no causal association for vaccination with health problems, but it is decided to temporarily suspend vaccination with vaccines of this series in Latvia for additional precautionary purposes.
Until now, vaccination with this series of vaccines has not been confirmed to cause health problems in Latvia.
9,600 doses of this vaccine series were delivered to Latvia on February 11, most of which have already been used. According to the vaccination data, 1,190 doses have not yet been used.
The decision of the Austrian national competent authority on the suspension of one of the AstraZeneca Covid-19 vaccine series is linked to the fact that one person was diagnosed with multiple thrombosis and died 10 days after vaccination, while another person has been hospitalized with pulmonary embolism after vaccination and continues treatment in hospital. An initial assessment by the European Medicines Agency shows that there is no causal association with this vaccine series with health problems and no specific safety risks have been identified for the vaccine series.
Until now, such medical conditions have not been known as side effects of this vaccine. The most common side effects with AstraZeneca are usually mild to moderate and pass within a few days of vaccination.
Both cases shall be evaluated by the European Medicines Agency in order to exclude any potential risks of this vaccine series.
This vaccine series ABV5300 was delivered to 17 EU Member States: Lithuania, Estonia, Luxembourg, Latvia, Ireland, Denmark, Austria, Greece, Sweden, the Netherlands, Poland, Spain, France, Iceland, Malta and Cyprus. This series includes 1.6 million doses.